Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki J, Sopala M, Avrameas A, Luo WL, Hueber W.
Dörner T, et al. Among authors: grader beck t.
Arthritis Rheumatol. 2024 Nov 18. doi: 10.1002/art.43059. Online ahead of print.
Arthritis Rheumatol. 2024.
PMID: 39557617